Table 3.
Correlation between the baseline biomedical characteristics of SA, DS, and the entire cohort and the expression of SSTR2 and SSTR5.
| Baseline GH | Baseline IGF-1 index | Baseline tumor volume |
|
|---|---|---|---|
| SA group | |||
| SSTR2 | r = −0.312 | r = 0.287 | r = −0.079 |
| P = 0.015 | P = 0.043 | P = 0.561 | |
| SSTR5 | r = 0.068 | r = −0.001 | r = −0.032 |
| P = 0.645 | P = 0.997 | P = 0.831 | |
|
| |||
| DS group | |||
| SSTR2 | r = −0.5 | r = 0.099 | r = −0.238 |
| P = 0.791 | P = 0.61 | P = 0.342 | |
| SSTR5 | r = −0.159 | r = 0.1 | r = −0.195 |
| P = 0.402 | P = 0.644 | P = 0.342 | |
|
| |||
| Entire cohort | |||
| SSTR2 | r = −0.228 | r = 0.019 | r = −0.125 |
| P = 0.032 | P = 0.866 | P = 0.284 | |
| SSTR5 | r = −0.029 | r = −0.229 | r = −0.108 |
| P = 0.8 | P = 0.051 | P = 0.391 | |
SA, pretreatment with somatostatin analogues before surgery; DS, direct surgery group; GH, growth hormone; IGF-1, insulin-like growth factor 1; SSTR, somatostatin receptor. The Pearson correlation coefficient was used to analyze the correlations between the immunoreactive score (IRS) and clinical parameters.